
Dr. Joe Geraci of NetraMark explains how AI analysis of clinical trial data can uncover hidden responder subgroups, separate true drug responders from placebo responders, and potentially rescue drug assets that appeared to fail in Phase II.

Dr. Joseph Geraci, PhD, is a mathematician, medical scientist, and AI innovator specializing in machine learning for complex clinical data. With postdoctoral training in machine learning, oncology, and neuropsychiatry, he has spent his career developing novel mathematical and artificial intelligence approaches to better understand heterogeneous patient populations and improve decision-making in drug development.
Dr. Geraci founded NetraMark, where he led the creation of NetraAI, a mathematically augmented AI platform designed to identify clinically meaningful patient subpopulations within small, complex datasets. His work is grounded in the belief that many clinical trial failures stem not from ineffective therapies, but from poor patient stratification—a challenge his technology was built to address. Over more than a decade of development, his research and leadership helped transform that idea into a platform used to support pharmaceutical and biotechnology companies in designing smarter, more precise clinical trials.

Dr. Joe Geraci of NetraMark explains how AI analysis of clinical trial data can uncover hidden responder subgroups, separate true drug responders from placebo responders, and potentially rescue drug assets that appeared to fail in Phase II.